Veterinarians Combine ChatGPT and AlphaFold to Slash Dog’s Tumor Size by 75%
Australian AI specialist Paul Conyngham has pioneered an experimental treatment for his dog, Rosie, who is battling incurable mast cell cancer. By leveraging a suite of advanced AI models including ChatGPT, AlphaFold, and Grok, Conyngham’s work represents a significant milestone in using generative AI for complex medical decisions.
Launched in November 2024, the initiative began with deep genomic sequencing of the tumor, guided by ChatGPT’s recommendations. Subsequently, AI systems identified specific target proteins and screened FDA-approved drugs for potential efficacy. The Grok model played a crucial role in designing the key vaccine component. Recent data shows the tumor has shrunk by approximately 75%. While not a complete cure, this success has drawn attention from industry giants like OpenAI’s Greg Brockman and DeepMind’s Demis Hassabis, highlighting AI’s potential in precision medicine.

Despite the optimism, biotech experts urge caution. Stanford chemical biology PhD Egan Peltan suggests the AI’s role may be overstated, noting that Rosie also received traditional immunotherapy, making it difficult to isolate the vaccine’s specific impact. Furthermore, the estimated cost for such personalized therapies ranges from $20,000 to $50,000, raising accessibility concerns.
While researchers emphasize that long-term safety and efficacy remain significant hurdles, this case illustrates how AI empowers non-medical professionals to navigate complex biological data. As tools like AlphaFold become more accessible, AI-driven personalized medicine is rapidly transitioning from lab concepts to real-world applications. Despite regulatory and clinical validation challenges, this interdisciplinary approach signals a fundamental shift in the efficiency of future medical research and development.
Related article
U.S. Stocks Hit Historic Milestone as AI and Aerospace Giants Prepare for Trillion-Dollar Debut
Elon Musk, Sam Altman, and Dario Amodei, three titans of the technology sector, are advancing toward initial public offerings for their respective ventures. With SpaceX, OpenAI, and Anthropic—three industry behemoths nearing trillion-dollar valuation
Swedish AI Startup Lovable Eyes $13.2 Billion Valuation After Major Funding Round
As AI-driven coding tools gain traction, Swedish startup Lovable has secured a major funding round. The company aims to raise $3 billion, potentially boosting its valuation to $13.2 billion—double the $6.6 billion recorded last December. Menlo Ventur
Google Tests Remy AI Agent for Gemini as Focus Shifts to User Control
According to Business Insider, Google is testing Remy, a new AI personal agent for Gemini. This tool aims to execute tasks on behalf of users, streamlining both professional workflows and daily routines.Currently, Remy is undergoing testing in an int
Related Special Topic Recommendations
Comments (0)
0/500
Australian AI specialist Paul Conyngham has pioneered an experimental treatment for his dog, Rosie, who is battling incurable mast cell cancer. By leveraging a suite of advanced AI models including ChatGPT, AlphaFold, and Grok, Conyngham’s work represents a significant milestone in using generative AI for complex medical decisions.
Launched in November 2024, the initiative began with deep genomic sequencing of the tumor, guided by ChatGPT’s recommendations. Subsequently, AI systems identified specific target proteins and screened FDA-approved drugs for potential efficacy. The Grok model played a crucial role in designing the key vaccine component. Recent data shows the tumor has shrunk by approximately 75%. While not a complete cure, this success has drawn attention from industry giants like OpenAI’s Greg Brockman and DeepMind’s Demis Hassabis, highlighting AI’s potential in precision medicine.

Despite the optimism, biotech experts urge caution. Stanford chemical biology PhD Egan Peltan suggests the AI’s role may be overstated, noting that Rosie also received traditional immunotherapy, making it difficult to isolate the vaccine’s specific impact. Furthermore, the estimated cost for such personalized therapies ranges from $20,000 to $50,000, raising accessibility concerns.
While researchers emphasize that long-term safety and efficacy remain significant hurdles, this case illustrates how AI empowers non-medical professionals to navigate complex biological data. As tools like AlphaFold become more accessible, AI-driven personalized medicine is rapidly transitioning from lab concepts to real-world applications. Despite regulatory and clinical validation challenges, this interdisciplinary approach signals a fundamental shift in the efficiency of future medical research and development.
U.S. Stocks Hit Historic Milestone as AI and Aerospace Giants Prepare for Trillion-Dollar Debut
Elon Musk, Sam Altman, and Dario Amodei, three titans of the technology sector, are advancing toward initial public offerings for their respective ventures. With SpaceX, OpenAI, and Anthropic—three industry behemoths nearing trillion-dollar valuation
Swedish AI Startup Lovable Eyes $13.2 Billion Valuation After Major Funding Round
As AI-driven coding tools gain traction, Swedish startup Lovable has secured a major funding round. The company aims to raise $3 billion, potentially boosting its valuation to $13.2 billion—double the $6.6 billion recorded last December. Menlo Ventur





Home






